Kidney Risk Stratification in Finerenone Treatment: FINEARTS

Name: Kidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial
Uploaded: 2025-04-01T04:00:00+00:00
Description: These video briefs feature expert insights on the latest clinical data presented at ACC 2025. Leading cardiologists discuss emerging nonsteroidal mineraloc

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Understanding Lipid and Lipoprotein Metabolism in Cardiovascular Health
Understanding Lipid and Lipoprotein Metabolism in Cardiovascular Health
Heart Matters
Understanding Lipid and Lipoprotein Metabolism in Cardiovascular Health
Sex-Based Differences in Lipid Management: Implications for Cardiovascular Risk
Sex-Based Differences in Lipid Management: Implications for Cardiovascular Risk
Heart Matters
Sex-Based Differences in Lipid Management: Implications for Cardiovascular Risk
New Insights in the Management of HCM: Exploring the Clinical Spectrum
New Insights in the Management of HCM: Exploring the Clinical Spectrum
CME/CE Broadcast Replay
New Insights in the Management of HCM: Exploring the Clinical Spectrum
0.50 credits
- Milind Y. Desai, MD, MBA
- Iacopo Olivotto, MD
- Elena Arbelo, MD, PhD
0.50 credits
Effect of Vericiguat on Heart Failure Hospitalization Events in Ambulatory Patients With HFrEF: VICTOR Trial Prespecified Analysis
Effect of Vericiguat on Heart Failure Hospitalization Events in Ambulatory Patients With HFrEF: VICTOR Trial Prespecified Analysis
Cardiology
Effect of Vericiguat on Heart Failure Hospitalization Events in Ambulatory Patients With HFrEF: VICTOR Trial Prespecified Analysis
- Javed Butler, MD, MPH, MBA

Kidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial

Kidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial

Recommended

Title

Share on ReachMD

Welcome to Global Cardiology Academy

Welcome to Global
Cardiology Academy